Portal de Periódicos da CAPES

Epistaxis Associated with Elevation of INR in a Patient Switched to Generic Warfarin—Another View

2000; Wiley; Volume: 20; Issue: 7 Linguagem: Inglês

10.1592/phco.20.9.866.35190

1875-9114

Bernd Meibohm, Wenhui Zhang, Ingrid Beierle, Marvin C. Meyer,

Coagulation, Bradykinin, Polyphosphates, and Angioedema

Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 20, Issue 7 p. 866-871 Epistaxis Associated with Elevation of INR in a Patient Switched to Generic Warfarin—Another View Dr. Bernd Meibohm Ph.D., Corresponding Author Dr. Bernd Meibohm Ph.D. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang) University of Tennessee, College of Pharmacy, 874 Union Avenue, Room 5p, Memphis, TN 38163; e-mail: [email protected]Search for more papers by this authorDr. Wenhui Zhang M.S., Dr. Wenhui Zhang M.S. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang)Search for more papers by this authorDr. Ingrid Beierle Pharm.D., Dr. Ingrid Beierle Pharm.D. Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis, TennesseeSearch for more papers by this authorDr. Marvin C. Meyer Ph.D., Dr. Marvin C. Meyer Ph.D. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang)Search for more papers by this author Dr. Bernd Meibohm Ph.D., Corresponding Author Dr. Bernd Meibohm Ph.D. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang) University of Tennessee, College of Pharmacy, 874 Union Avenue, Room 5p, Memphis, TN 38163; e-mail: [email protected]Search for more papers by this authorDr. Wenhui Zhang M.S., Dr. Wenhui Zhang M.S. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang)Search for more papers by this authorDr. Ingrid Beierle Pharm.D., Dr. Ingrid Beierle Pharm.D. Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis, TennesseeSearch for more papers by this authorDr. Marvin C. Meyer Ph.D., Dr. Marvin C. Meyer Ph.D. Departments of Pharmaceutical Sciences (Drs. Meibohm and Meyer, and Ms. Zhang)Search for more papers by this author First published: 17 January 2012 https://doi.org/10.1592/phco.20.9.866.35190Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Haines S.T.. Reflections on generic warfarin. Am J Health-Syst Pharm 1998; 55: 72–33. 2 Benson S.R., Vance-Bryan K.. In favor of Coumadin over generic warfarin. Am J Health-Syst Pharm 1998; 55: 727–9. 3 Wittkowsky A.K.. Generic warfarin: implications for patient care. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1997; 17: 640–3. 4 Meyer M.C., Chan K., Bolton S.. Generic warfarin: implications for patient care—another view. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1998; 18: 884–6. 5 Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations, 19th ed. Rockville, MD; 1999. 6 Wagner J.L., Dent L.A.. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2000; 20(2): 240–3. 7 GiaQuinto N.J.. Are all warfarin preparations alike? A comprehensive overview of current data, emerging opinions, and perspectives. J Thromb Thrombolysis 2000; 9: 139–44. 8 Vadher B., Patterson D.L., Leaning M.. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. Br J Clin Pharmacol 1999; 48: 63–70. 9 Holford N.H.G.. Clinical pharmacokinetics and pharmaco-dynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483–504. 10 United States Pharmacopoeia. Content uniformity 2001–2002.. Rockville, MD: USP 24 Convention, 2000. 11 Hylek E.M., Heiman H., Skates S.J., Sheehan M.A., Singer D.E.. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657–62. 12 Neutel J.M., Smith D.H.G.. A randomized, crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998; 19: 49–59. 13 Handler J., Nguyen T.T., Rush S., Pham N.T.. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol 1998; 4: 13–20. 14 Swenson C.N., Fundak G.. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health-Syst Pharm 2000; 57: 452–5. 15 Plowman B.K., Morreale A.P., Mehdigholi E.. A comparative analysis of Coumadin and generic warfarin [abstr]. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2000; 20: 346. 16 Noviasky J.A.. Evidence-based pharmacy versus opinion on generic product selection of warfarin. Am J Health-Syst Pharm 1999; 56: 2246–7. References 1 Wagner J.L., Dent L.A.. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2000; 20(2): 240–3. 2 Murphy J.E.. Generic substitution and optimal patient care. Arch Intern Med 1999; 159: 429–33. 3 GiaQuinto N.J.. Are all warfarin preparations alike? A comprehensive overview of current data, emerging opinions, and perspectives. J Thromb Thrombolysis 2000; 9: 139–44. 4 Olin B.R. Kastrup, eds. Facts and comparisons drug information. St. Louis, MO: Lippincott, 2000: 583. 5 Pfizer. Viagra (sildenafil) package insert. New York, NY; 1999. 6 Michalets E.L.. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1998; 18(1): 84–112. 7 Olin B.R. Kastrup, eds. Facts and comparisons drug information. St. Louis, MO: Lippincott, 2000: 177. 8 Handler J., Nguyen T.T., Rush S., Pham N.T.. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin®. Preventative Cardiology 1998; 4: 13–20. 9 Neutel J.M., Smith D.H.G.. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin®. Cardiovasc Rev Rep 1998; 19: 49–89. Citing Literature Volume20, Issue7July 2000Pages 866-871 ReferencesRelatedInformation